THE takeover of Celltech, the company that was supposed to be the core of the British biotech industry, by a company from Belgium of which few people had heard, should not be passed off as anything other than a disaster. Yet again, Britain has pioneered in a new business, got its fair share of patents and inventions and failed to turn it into a profitable, world-leading business.